Lab2Market: A novel strategy towards the computational development of peptide 'disruptors' to be used as molecular probes or therapeutic molecules.

通过Lab2Market合作伙伴计划，我们计划将能够快速筛选和开发新型多肽疗法的软件推向市场。事实上，药物输送游戏中的领跑者包括小分子药物和大分子药物，但还有一类药物正好落在两者之间：多肽。自1921年推出用于治疗糖尿病的胰岛素多肽以来，已有100多种多肽药物进入市场，治疗包括癌症、多发性硬化症、艾滋病毒感染和慢性疼痛在内的多种疾病(自2017年以来有10种多肽)。多肽疗法的新市场增长已经导致&gt；150种多肽进入临床开发，另一种&gt；600多肽正在进行临床前研究。该市场的增长速度比任何其他疗法都快，估计每年约为400亿美元，与小分子药物相比，批准率翻了一番。为了直接应对在生产新多肽以实现市场增长方面的挑战，我们开发了TIPS(In Silico多肽合成器)，这是一种开发基于多肽的抑制剂的计算方法。这一计算流水线有望减少有效设计靶向特异性抑制剂所需的时间和研究筛选成本。我们的目标是进行市场评估，以确定将我们的软件许可给主要行业合作伙伴的适当战略。

Through the Lab2Market partner program, we are proposing to bring to market software that enables rapid screening and development of novel peptide therapeutics. Indeed, the front runners in the game of drug delivery include small molecule and large molecule drugs, but there is another class that lands right in between; peptides. Since the introduction of insulin peptides for the treatment of diabetes in 1921, more than 100 peptide drugs have reached the market for a number of diseases, including cancer, multiple sclerosis, HIV infection, and chronic pain (10 peptides since 2017). New market growth into peptide therapeutics has resulted in >150 peptides in clinical development and another >600 peptides undergoing preclinical studies. The market is growing faster than any other therapeutics and is estimated at >$40 billion per year, with a double approval rate compared to small molecule drugs. To directly address challenges in generating new peptides to permit market growth, we have developed TIPS (The In silico Peptide Synthesizer), a computational method for developing peptide-based inhibitors. This computational pipeline promises to decrease the time and research screening costs to efficiently design target-specific inhibitors. Our objective is to carry out a Market Assessment to determine appropriate strategies to license our software to key industry partners.